These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8549033)

  • 1. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
    Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
    Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
    Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
    Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
    Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
    Krivoruk Y; Kinirons MT; Wood AJ; Wood M
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
    Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
    Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
    Cakaloglu Y; Tredger JM; Devlin J; Williams R
    Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.
    Turgeon DK; Leichtman AB; Blake DS; Schmouder RL; Lown KS; Annesley TM; Watkins PB
    Transplantation; 1994 Jun; 57(12):1736-41. PubMed ID: 8016878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
    Chiou WL; Jeong HY; Wu TC; Ma C
    Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythromycin breath test and clinical transplantation.
    Watkins PB
    Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
    Kinirons MT; O'Shea D; Downing TE; Fitzwilliam AT; Joellenbeck L; Groopman JD; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1993 Dec; 54(6):621-9. PubMed ID: 8275617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes.
    Irshaid Y; Branch RA; Adedoyin A
    Drug Metab Dispos; 1996 Feb; 24(2):164-171. PubMed ID: 8742227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
    Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythromycin breath test.
    Rivory LP; Watkins PB
    Clin Pharmacol Ther; 2001 Oct; 70(4):395-9. PubMed ID: 11673756
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the erythromycin breath test for use in cancer patients.
    Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
    Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
    Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
    Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythromycin breath test.
    Watkins PB
    Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.